CRISPR Therapeutics AG Business Operations Contracts & Agreements
11 Contracts & Agreements
- Advisory Agreements (1 contract)
- Collaboration Agreements (6)
- Development Agreements (2)
- Services Agreements (1)
- Termination Agreements (1)
- Amendment No. 1 to the Amended and Restated Joint Development and Commercialization Agreement, dated December 12, 2023, by and between, on the one hand, Vertex Pharmaceuticals... (Filed With SEC on December 13, 2023)
- First Amendment to the Strategic Collaboration and License Agreement dated March 17, 2021, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (Filed With SEC on April 27, 2021)
- Amendment No. 2 to Research Collaboration Agreement by and between CRISPR Therapeutics AG and ViaCyte, Inc., dated as of October 21, 2019 (Filed With SEC on February 12, 2020)
- Amendment No. 1 to Research Collaboration Agreement by and between CRISPR Therapeutics AG and ViaCyte, Inc., dated as of April 30, 2019 (Filed With SEC on February 12, 2020)
- Termination Agreement, dated December 27, 2019, by and between CRISPR Therapeutics AG and Rodger Novak (Filed With SEC on December 27, 2019)
- Strategic Collaboration and License Agreement dated June 6, 2019, between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated (Filed With SEC on July 29, 2019)
- Amendment No. 2 to the Strategic Collaboration, Option and License Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals... (Filed With SEC on July 29, 2019)
- Advisory Agreement by and between CRISPR Therapeutics AG and Dr. Anthony Coles, dated as of December 20, 2017 (Filed With SEC on December 21, 2017)
- Amendment No. 1 to the Strategic Collaboration, Option and License Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals... (Filed With SEC on December 18, 2017)
- Joint Development and Commercialization Agreement by and between, on the one hand, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals (Europe) Limited, and on the... (Filed With SEC on December 18, 2017)
- [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEENFILED WITH THE SECURITIES AND EXCHANGE... (Filed With SEC on December 16, 2016)
